The B203.13 monoclonal antibody was developed by immunizing mice with the B/monocyte biphenotypic cell line B1b. During normal hematopoiesis B203.13 is expressed on a fraction of CD34+ cells, while on mature cells it is only present on B-lymphocytes. We tested this antibody as a marker of childhood B-acute lymphoblastic leukemia (B-ALL). Bone marrow aspirates from 139 cases of early B-ALL and 25 controls were studied. About 40% of the B-ALL patients expressed B203.13. In these patients, B203.13 was constantly co-expressed with CD10, but never co-expressed with CD20, contrary to the controls. The CD10(+)/B203.13(+) phenotype was specific to B-ALL, since CD10(+)/CD20(+) cells from common acute lymphoblastic leukemia (c-ALL) did not express B203.13. We concluded that the use of B203.13 in association with CD10 and CD20 provides meaningful information for distinguishing normal residual B-cells from leukemic B-lymphoblasts and that recurrence of a CD10(+)/B203.13(+) phenotype after transplantation may be a very early relapse indicator of early B-acute lymphoblastic leukemia

Aberrant expression of B203.13 antigen in acute lymphoid leukemia of B-cell origin / Gobbi, Giuliana; Mirandola, Prisco; Malinverno, C.; Sponzilli, Ivonne; Carubbi, Cecilia; Ricci, F.; Binazzi, R.; Basso, G.; GIULIANI PICCARI, G.; Ramazzotti, G.; Pasquantonio, G.; Cocco, L.; Vitale, Marco. - In: INTERNATIONAL JOURNAL OF ONCOLOGY. - ISSN 1019-6439. - 33:(2008), pp. 371-374. [10.3892/ijo_00000017]

Aberrant expression of B203.13 antigen in acute lymphoid leukemia of B-cell origin.

GOBBI, Giuliana;MIRANDOLA, Prisco;SPONZILLI, Ivonne;CARUBBI, Cecilia;VITALE, Marco
2008-01-01

Abstract

The B203.13 monoclonal antibody was developed by immunizing mice with the B/monocyte biphenotypic cell line B1b. During normal hematopoiesis B203.13 is expressed on a fraction of CD34+ cells, while on mature cells it is only present on B-lymphocytes. We tested this antibody as a marker of childhood B-acute lymphoblastic leukemia (B-ALL). Bone marrow aspirates from 139 cases of early B-ALL and 25 controls were studied. About 40% of the B-ALL patients expressed B203.13. In these patients, B203.13 was constantly co-expressed with CD10, but never co-expressed with CD20, contrary to the controls. The CD10(+)/B203.13(+) phenotype was specific to B-ALL, since CD10(+)/CD20(+) cells from common acute lymphoblastic leukemia (c-ALL) did not express B203.13. We concluded that the use of B203.13 in association with CD10 and CD20 provides meaningful information for distinguishing normal residual B-cells from leukemic B-lymphoblasts and that recurrence of a CD10(+)/B203.13(+) phenotype after transplantation may be a very early relapse indicator of early B-acute lymphoblastic leukemia
Aberrant expression of B203.13 antigen in acute lymphoid leukemia of B-cell origin / Gobbi, Giuliana; Mirandola, Prisco; Malinverno, C.; Sponzilli, Ivonne; Carubbi, Cecilia; Ricci, F.; Binazzi, R.; Basso, G.; GIULIANI PICCARI, G.; Ramazzotti, G.; Pasquantonio, G.; Cocco, L.; Vitale, Marco. - In: INTERNATIONAL JOURNAL OF ONCOLOGY. - ISSN 1019-6439. - 33:(2008), pp. 371-374. [10.3892/ijo_00000017]
File in questo prodotto:
File Dimensione Formato  
013.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 154.67 kB
Formato Adobe PDF
154.67 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2431067
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact